State of the Cybersecurity Workforce: New ISACA Research Shows Highest Retention Difficulties in Years
The Great Resignation is plaguing industries across the board—but it’s especially challenging within in-demand fields like cybersecurity. According to ISACA’s new survey report, State of Cybersecurity 2022: Global Update on Workforce Efforts, Resources and Cyberoperations, organizations are struggling more than ever with hiring and retaining qualified cybersecurity professionals and managing skills gaps.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220323005803/en/
ISACA surveyed information security professionals across the globe for the eighth year in a row in its State of Cybersecurity 2022 survey. See what more than 2,000 security leaders had to say about workforce challenges and opportunities. (Photo: Business Wire)
The eight annual survey features insights from more than 2,000 cybersecurity professionals around the globe, and examines cybersecurity staffing and skills, resources, cyberthreats and cybersecurity maturity.
Hiring and retention challenges
As in past years, filling cybersecurity roles and retaining talent continues to be a challenge for many enterprises. Sixty-three percent of respondents indicate they have unfilled cybersecurity positions, up eight percentage points from 2021. Sixty-two percent report that their cybersecurity teams are understaffed. One in five say it takes more than six months to find qualified cybersecurity candidates for open positions.
Sixty percent of respondents report difficulties retaining qualified cybersecurity professionals, up seven percentage points from 2021. The top reasons that cybersecurity professionals are leaving their jobs include:
- Recruited by other companies (59 percent)
- Insufficient salary or bonus (48 percent)
- Limited advancement opportunities (47 percent)
- High stress levels (45 percent)
- Poor management support (34 percent)
Skills gaps and mitigation
Respondents note that the top skills gaps they see in today’s cybersecurity professionals are soft skills (54 percent), cloud computing (52 percent) and security controls (34 percent). Soft skills also top the list of skills gaps among recent graduates, at 66 percent.
To address these skills gaps, respondents note that cross training of employees and increased use of contractors and consultants (up five percentage points from the year prior) are the main ways they mitigate technical skill gaps. Just over half (52 percent) say their enterprises require university degrees, a six-percentage-point decrease from 2021.
“The Great Resignation is compounding the long-standing hiring and retention challenges the cybersecurity community has been facing for years, and systemic changes are critical,” says Jonathan Brandt, ISACA Director, Professional Practices and Innovation. “Flexibility is key. From broadening searches to include candidates without degrees to providing support, training and flexible schedules that attract and retain qualified talent, organizations can move the needle in strengthening their teams and closing skills gaps.”
Forty-two percent say their cybersecurity budgets are appropriately funded—the highest percentage in eight years, up five percentage points from 2021, and the most favorable report since ISACA began doing this survey. Fifty-five percent of respondents also expect their enterprises to have budget increases, while 38 percent expect no change, and multiyear data suggests budgets are leveling.
This year, 43 percent of respondents indicate that their organization is experiencing more cyberattacks, an eight-percentage-point increase from 2021.
Enterprise reputation (79 percent), data breach concerns (70 percent) and supply chain disruptions (54 percent) are the top concerns related to cyberattacks for respondents. While ransomware attacks top the headlines, the survey found that ransomware attacks have remained virtually unchanged from last year, at 10 percent. Other top types of cyberattacks experienced in the past year include:
- Social engineering (13 percent)
- Advanced persistent threat (12 percent)
Security misconfiguration (10 percent)
Ransomware (10 percent)
Unpatched system (9 percent)
Denial of service (9 percent)
Despite the threats they face, 82 percent of respondents—an all-time high, and a five-percentage-point increase from last year—indicate they are confident in their cybersecurity team’s ability to detect and respond to cyberthreats.
When it comes to cyberrisk assessments, 41 percent of survey respondents say their enterprises conduct them annually, up two percentage points from last year. One-third of respondents say their enterprise conducts them more than annually.
Brandt and Mark St. John, senior vice president, product, at LookingGlass Cyber Solutions, will discuss these findings further in a free webinar taking place on 31 March at 12:00 PM EDT (4 PM UTC). To register, visit https://store.isaca.org/s/lt-event?id=a334w000004gM03AAE.
“It’s important to understand the trends across the community over time as well as how one’s organization compares. This is necessary information to help advance the field as a whole, and we’re proud to be a part of sharing and disseminating these insights,” says Mary Yang, Chief Marketing Officer at LookingGlass Cyber Solutions. “LookingGlass is thrilled to support the cybersecurity community by partnering with ISACA on this report.”
The State of Cybersecurity 2022 survey report is free at www.isaca.org/state-of-cybersecurity-2022.
ISACA leverages the expertise of its more than 150,000 members who work in information security, governance, assurance, risk and privacy to drive innovation through technology. It has a presence in 188 countries, including more than 220 chapters.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Emily Van Camp, email@example.com, +1.847.385.7223
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda and Seagen to Highlight ADCETRIS ® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma26.5.2022 23:25:00 CEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502) and Seagen Inc., (NASDAQ:SGEN) today announced that overall survival (OS) data from the Phase 3 ECHELON-1 clinical trial of an ADCETRIS® (brentuximab vedotin) plus chemotherapy combination will be presented in an oral session at the 59th American Society of Clinical Oncology (ASCO) Annual Meeting on Friday, June 3, 2022, 1:00-4:00 PM CT, and at the 27th European Hematology Association (EHA) Annual Meeting on Friday, June 10, 2022, 11:30 – 12:45 CEST. “The longer-term follow-up data from the ECHELON-1 trial have significant clinical importance, as this trial represents one of only two frontline randomized studies in advanced stage Hodgkin lymphoma that shows an overall survival advantage for the experimental arm,” said Stephen Ansell, M.D., Ph.D., Mayo Clinic, and ECHELON-1 study investigator. “These results clearly show that the addition of brentuximab vedotin to chemotherapy improves the long-term outcome of patients and the combination
Ipsen: ASCO 2022: New Cabometyx ® Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types Including Metastatic Non-Small Cell Lung Cancer26.5.2022 23:00:00 CEST | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced encouraging data to be presented for the multi-targeted tyrosine kinase inhibitor (TKI), Cabometyx® (cabozantinib), across a range of cancer types at this year’s American Society of Clinical Oncology Annual Meeting (ASCO 2022) to be held on 3-7 June. Data presentations will include findings in metastatic non-small cell lung cancer (NSCLC), as well as established indications of advanced renal cell carcinoma and radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC). These data show that the therapeutic potential of Cabometyx as a key treatment option in a broad range of tumors is continuing to be realized. Updated outcomes from the multicenter Phase Ib COSMIC-021 trial evaluating the combination of Cabometyx plus atezolizumab in an expanded patient population in metastatic NSCLC demonstrate encouraging clinical activity with manageable toxicity in people previously treated with an immune checkpoint inhib
New Better Dispensing Videos from Nordson EFD Explain Jetting Technology and How to Choose the Right Solution26.5.2022 19:00:00 CEST | Press release
Nordson EFD, a Nordson company (NASDAQ: NDSN) and leading precision fluid dispensing systems manufacturer, introduces a new Better Dispensing™ How-To Video series. These three highly educational videos presented by EFD application specialist, Tom Muccino, provide best practices for choosing between contact dispensing and non-contact (jet) dispensing, and how to select the best jetting valve for a manufacturing application. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220510006079/en/ xQR41 Series MicroDot™ needle valve (left) and PICO Pµlse XP jet valve (right). (Photo: Business Wire) “One of the main differences is that with jetting, your valve never touches the surface of the part. Instead, your fluid “flies” or “jets” out of the valve, which is above the part,” Muccino explains in the first video. “This makes jetting perfect for fragile or complex parts.” Nordson EFD provides a wide range of contact and non-contact (jet
Medisca Drives Worldwide Access to Thyroid through Distribution License with SUANFARMA26.5.2022 18:17:00 CEST | Press release
On March 16, 2022, Medisca, a global supplier of pharmaceutical ingredients and equipment, entered into an exclusive agreement with SUANFARMA, a European-based manufacturer and distributor of pharmaceutical ingredients, for the global supply and distribution of Thyroid Powder, USP, by leveraging its exclusive partnership with pharmaceutical manufacturer, Sichuan Deebio Pharmaceutical Co., Ltd (Deebio). “Partnering with Deebio in June 2021 was a huge milestone for the pharmaceutical compounding industry as it allowed us to secure and stabilize the supply of high quality Thyroid Powder for the US market,” said Panagiota Danopoulos, Senior Vice President of Global Strategy & Innovation at Medisca. “After going to market, we immediately realized that the demand for Thyroid Powder extended outside of our usual distribution channels to compounding pharmacies,” continued Danopoulos. “And we had the capacity to upscale supply to make this critical ingredient accessible to various markets, chan
Merck to Present Latest Research From Oncology Portfolio at ASCO 202226.5.2022 18:00:00 CEST | Press release
Merck, a leading science and technology company, today announced the latest research representing the Company’s innovative oncology portfolio has been accepted for presentation at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, 2022. Data encompass Company-sponsored, investigator-sponsored, and external collaboration studies. Abstracts to be shared at the meeting include data for the Company’s licensed medicines BAVENCIO® (avelumab), TEPMETKO® (tepotinib) and ERBITUX® (cetuximab), and its oncology pipeline. The presentations span key tumor types including advanced urothelial carcinoma (UC), advanced renal cell carcinoma (RCC), metastatic non-small cell lung cancer (NSCLC), metastatic colorectal cancer (CRC), and head and neck cancer (SCCHN). “We look forward to coming together with the scientific community at ASCO 2022, where we will share the latest data from our portfolio, which demonstrate our determination to make a real difference in the lives of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom